Virdante: Superpowering Sialylation

Intravenous immune globulin products provide symptomatic relief for autoimmune and inflammatory conditions when given at high doses. Virdante Pharmaceuticals Inc. is developing an IVIG product that is 10 times more potent in preclinical models, which could provide advantages in dosing, cost of goods and tolerability.

Virdante was founded by Jeffrey Ravetch, an immunology professor at Rockefeller University, based on 10 years of research designed to better understand and ultimately improve upon IVIG, a plasma-derived product containing pooled IgG antibodies...